Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2021-12-01

Summary

This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: University of Alabama at Birmingham
• Collaborators: Novartis Pharmaceuticals; Tracon Pharmaceuticals Inc.
• Treatments: Antibodies, Monoclonal; Everolimus; Hormones; Letrozole; Sirolimus